



Reader’s Digest der Pathophysiologie von 
Knochenmetastasen 
Zusammenfassung  Knochenmetastasen  basieren  auf 
einen Prozess der ursprünglich als seed and soil Theorie 
im achtzehnten Jahrhundert beschrieben wurde. Tumor-
zellen  die  von  Patienten mit  Brust-  oder  Prostatakrebs 
stammen  nützen  häufig  den  Knochen  um  außerhalb 
der  primären  Tumorlokalisation  zu  wachsen.  Zu  den 
schwerwiegenden klinische Folgen von Knochenmetas-
tasen zählen Schmerzen, Frakturen und Hyperkalzämie, 
die  sich  letztlich  aus  einem massiven Ungleichgewicht 
des  Knochenumbaus  ergeben.  Die  meisten  Knochen-
metastasen  verursachen  katabole  Veränderungen  des 
Knochenumbaus.  Die  Schwere  der  Knochenresorption 
ist  mit  dem  Tumorwachstum  assoziiert,  was  auf  die 
Existenz  eines  Teufelskreises  hinweist,  der  unterbro-
chen  werden  muss.  Osteoblastische  Metastasen,  wie 




liche  Grundlage  für  therapeutische  Interventionen  auf 
verschiedenen  Ebenen,  einschließlich  dem  „Homing“ 
der  Tumore  in  den  Knochen,  das  Überleben  und  das 
Wachstum der  Tumorzellen  im Knochen,  und  die Me-
chanismen des Knochenabbaus.
Schlüsselwörter:  Knochenmetastasen,  osteolytische  Me-
tastasen,  osteosklerotische  Läsionen,  Knochenresorption, 
Osteoblasten, Osteoklasten
Summary  Bone metastases are a process originally pro-
posed  as  the  “seed  and  soil  theory”  in  the  eighteenth 
century.  Tumor  cell  disseminating  from  patients  with 
breast or prostate cancer typically use the bony environ-
ment  to  grow  outside  the  primary  tumor  location. The 
severe  clinical  consequences  of  bone  metastasis  such 
as pain, fractures, and hypercalcemia result from a seri-
ous misbalance of bone turnover. Most bone metastases 
cause  catabolic  changes  of  bone  turnover. The  severity 
of bone resorption is associated with tumor growth, sug-
gesting the existence of a vicious cycle that needs to be 
interrupted.  Osteoblastic  metastasis  showing  signs  of 













of  bone metastases. The  aim  of  this  short  review  is  to 
provide a primer  for  the  readers of  this  special  issue of 
Wiener Medizinische Wochenschrift  to  follow my  steps 
and have the references available. I have explicitly aban-
doned to fill the summary with the original literature as 
this  approach  has  already  been  done  by  the  dedicated 
experts.  Thus,  the  short  summary  should  be  conside-
red as the reader’s digest of the recent reviews on bone 
metastases.
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and  bone  cells  [1,  2].  Primary  tumors  originating  from 
the bone include osteosarcoma [3] and chondrosarcoma 
[4], however the vast majority are secondary tumors dis-















Bone metastases  can  negatively  interfere  with  bone 
turnover besides their devastating impact on the immune 
and hematopoietic system. The patients’ morbidity and 
ultimately  also mortality  is  a  consequence of hypercal-













tumor  cells  to  “home”  to  bone  tissue?  (ii) What  is  the 
microenvironment required tumor growth? (iii) How can 
tumor cells stimulate bone resorption? (iv) What marks 
the  difference  between  lytic  and  osteoblastic  metasta-




information  accumulated  from more  extensive  current 
reviews [8–13].
What mechanisms allow the disseminating tumor 
cells to “home” to bone tissue?
The primary tumor releases “disseminating tumor cells” 
that  can  enter  the  circulation  and  reach  all  tissues, 





nism  strongly  resembles  the  situation where  therapeu-
tically  transplanted  hematopoietic  stem  cells  “home” 
to  their niches  in  the bone marrow, which  is  crucial  to 
restart hematopoiesis. A current hypothesis supports the 
concept  that  tumor  cells  and  hematopoietic  stem  cells 
express similar adhesion molecules, respond to the same 
signals and consequently compete for the same niches. 
One  central  regulator  is  the  chemokine CXCL12  (syno-
nym  for  stromal  cell-derived  factor  1;  SDF-1)—CXCR4-
axis. CXCL12 is strongly expressed by mesenchymal cells 
of the bone marrow including osteoblasts, thus providing 
a  chemotactic  gradient  that  can attract CXCR4-positive 





also  contribute  to  keep  the  tumor  cells  in  a  dormant 
state.  Tumor  cells  can  persist  for  years  in  their  niches 
before the growth and expansion of the tumor cells is ini-
tiated by the yet poorly defined stimuli.
What is the microenvironment required for tumor 
growth?
Tumor  growth  requires  bone  resorption.  In  animal 
models  typically  associated  with  high  bone  turnover, 
e.g.  following  ovariectomy  and  vitamin D  and  calcium 










hormone-related  protein  (PTHrP)  expression.  Even 
though  antiresorptive  therapies  are  primarily  indica-
ted  to control  the  skeletal  related events,  they have  the 
potential to improve disease free survival, as reported for 
premenopausal with estrogen responsive early stage bre-
ast  cancer  [14]. Overall  targeting  bone  turnover maybe 
one  strategy  to  counteract  bone metastasis  and  tumor 
growth  as  summarized  in  recent  reviews  [11,  15,  16]. 




How can tumor cells stimulate bone resorption?
The  best-described  mechanism  of  bone  destruction  is 




to  this hypothesis,  tumor cells produce PTHrP  that can 
cause a shift in the RANKL-osteoprotegerin ratio favoring 
the  formation,  activity,  and  survival  of  bone-resorbing 
osteoclasts. The osteoclasts in turn release growth factors 
including transforming growth factor-β(TGF−β) from the 
bone matrix  which  can  support  osteoclastogenesis  but 
also serves as stimulus for the tumor cells to expand and 
to produce even more PTHrP. Support for this hypothesis 
comes  from  preclinical  research  showing  transcription 
inhibitors  of  the  PTHrP  promoter  reduced  hypercal-




likely  because  the  molecules  are  pleiotropic  in  nature 
and blocking might cause severe side effects. The vicious 
cycle  is  presumably more  complex  because  tumor  and 
bone-derived molecules such as PTHrP and TGF-β can 
affect  the  immune  cells, which  in  turn  can  affect  bone 
turnover. The overall consequence of bone metastases is 
that tumor growth occurs at the expense of bone loss.




resulting  in  a  negative  balance  of  bone  turnover.  Lytic 
bone metastasis make the larger part of secondary tumor 
in bone, but there are also osteoblastic metastases where 
bone  formation  exceeds  bone  resorption.  Osteoblas-
tic metastases are  typically observed  in prostate cancer 
showing signs of osteosclerotic lesions. Thus, the tumor 
cells  can  cause pathologic bone  formation;  even  tough 
initially  tumor growth  is also associated with  increased 




supporting  osteoblastogenesis  and  their  activity  such 
as those of Wnt-family;  the fibroblast-like growth factor 
(FGF)-family  and  bone morphogenetic  protein  (BMP)-








sensitive  to Wnt  ligands. The clinical relevance of  these 
findings  remains unclear. Moreover,  there are hypothe-
ses  that  prostate  cancer  cells  transdifferentiate  into  a 
bone-forming  osteoblastic  cell. Overall, more  informa-
tion is required to better understand the autocrine para-
crine  function  of  prostate  cancer  cells within  the  bony 
microenvironment.




cells  accumulating  in  the  bone  tissue  exhibit  a  strong 
osteolytic  potential. The  high  levels  of  RANKL  expres-
sion  by  the  plasma  cells  can  provoke  osteoclastogene-
sis  and  activation  in  the bony  environment,  and might 
thus explain  the severe resorption. Also  the chemokine 
CCL3  (macrophage  inflammatory  protein-1α)  MIP-1α 
is considered a key regulator of bone destruction, often 
expressed  by  plasma  cells.  Pathologic  fractures,  pain, 
and hypercalcemia are the symptoms of a disease which 
are not treated or insufficiently treated with antiresorp-













Future  research  directions  are  basically  focused  on 
the understanding of the “seed and soil” theory and the 
way  the  tumor  cells  interfere  with  bone  turnover. The 
devastating  effects  of  bone  metastases  are  the  conse-
quence of a  sequential process  that holds  the potential 
to  interfere  at  the  various  levels  related  to  the  original 
question posed at the beginning of this review: “homing” 
of tumors to bone, survival and growth of the tumor cell 
in  the  bone  niche  and  the  mechanisms  causing  bone 
destruction. Therapeutic strategies can be based on the 
various  levels,  however  further  understanding  of  the 
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